Literature DB >> 7658053

Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology.

S H Khoo1, A S Bailey, J C de Jong, B K Mandal.   

Abstract

Prospective surveillance of 63 human immunodeficiency virus (HIV)-positive patients and 9 HIV-negative partners over 5-27 months yielded 51 adenoviruses from 18 HIV-positive patients. These were serotyped and compared by restriction enzyme analysis (REA) together with 24 isolates from 19 other HIV-positive patients. The actuarial risk of infection at 1 year in HIV-positive patients was 28% (17% with entry CD4 cell count of > 200/mm3 and 38% with CD4 cell count of < or = 200/mm3, P = .03). The most frequent site of infection was gastrointestinal (17/18 patients) with mainly subgenus D adenoviruses, while urinary infection was caused by subgenus B or D. Prolonged fecal excretion (2-27 months) was associated with CD4 cell counts < 150/mm3. Identical strains were seen in 2 HIV-positive partners and 2 unrelated patients. Gastrointestinal infection was temporally associated with diarrhea in only 7 (41%) of 17 cases. The remainder (59%) were asymptomatic or minimally symptomatic, and diarrhea was often caused by other opportunistic pathogens.

Entities:  

Mesh:

Year:  1995        PMID: 7658053     DOI: 10.1093/infdis/172.3.629

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D.

Authors:  Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh
Journal:  FEBS Lett       Date:  2019-12-11       Impact factor: 4.124

Review 2.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.

Authors:  J C De Jong; A G Wermenbol; M W Verweij-Uijterwaal; K W Slaterus; P Wertheim-Van Dillen; G J Van Doornum; S H Khoo; J C Hierholzer
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 4.  Adenoviruses in immunocompromised hosts.

Authors:  Marcela Echavarría
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

5.  Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men.

Authors:  Marcel E Curlin; Meei-Li Huang; Xiaoyan Lu; Connie L Celum; Jorge Sanchez; Stacy Selke; Jared M Baeten; Richard A Zuckerman; Dean D Erdman; Lawrence Corey
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

Review 6.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

7.  A Summary of the Second Annual HIV Microbiome Workshop.

Authors:  Brett Williams; Mimi Ghosh; Charles A B Boucher; Frederic Bushman; Stacy Carrington-Lawrence; Ronald G Collman; Satya Dandekar; Que Dang; Angela Malaspina; Roger Paredes; Cara C Wilson; Piotr Nowak; Nichole R Klatt; Laurel Lagenaur; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2017-10-26       Impact factor: 2.205

Review 8.  Viruses and kidney disease: beyond HIV.

Authors:  Meryl Waldman; Vickie Marshall; Denise Whitby; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2008-11       Impact factor: 5.299

9.  PCR method for detection of adenovirus in urine of healthy and human immunodeficiency virus-infected individuals.

Authors:  M Echavarria; M Forman; J Ticehurst; J S Dumler; P Charache
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

10.  Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.

Authors:  Junji Uchino; David T Curiel; Hideyo Ugai
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.